OTCMKTS:BETRF

BetterLife Pharma Stock Forecast, Price & News

$0.66

-0.01 (-1.49 %)

(As of 04/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.66

Now: $0.66▼

$0.72

50-Day Range

$0.67

MA: $1.03▼

$1.20

52-Week Range

$0.25

Now: $0.66▼

$2.59

Volume24,489 shs

Average Volume85,848 shs

Market Capitalization$11.37 million

P/E RatioN/A

Dividend YieldN/A

Beta3.8

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumours to treat various types of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was founded in 2002 and is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:BETRF

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.abetterlifepharma.com

Phone(604) 805-7783

Employees7

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio0.16

Quick Ratio0.16

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.12 per share

Price / Book5.50

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-14,780,000.00

Net MarginsN/A

Return on Equity-734.15%

Return on Assets-219.66%

Miscellaneous

Outstanding Shares17,211,000

Market Cap$11.37 million

Next Earnings Date6/7/2021 (Estimated)

OptionableNot Optionable

Headlines

BetterLife Pharma Inc. (OTCMKTS:BETRF) Short Interest Up 3,000.0% in March
April 13, 2021 | americanbankingnews.com

Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor
April 8, 2021 | finance.yahoo.com

BetterLife Added to Horizons Psychedelic Stock Index ETF
March 29, 2021 | finance.yahoo.com

Short Interest in BetterLife Pharma Inc. (OTCMKTS:BETRF) Declines By 61.5%
March 28, 2021 | americanbankingnews.com

BetterLife Pharma says subsidiary Altum Pharmaceuticals to conduct coronavirus trial in Chile using its AP-003
March 26, 2021 | proactiveinvestors.com

BetterLife Pharma inks research agreement with the University of California San Diego
March 26, 2021 | proactiveinvestors.com

BetterLife Pharma: BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies
March 24, 2021 | finanznachrichten.de

BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies
March 24, 2021 | finance.yahoo.com

BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003
March 11, 2021 | finance.yahoo.com

BetterLife Pharma announces tie-up with Carleton University to study TD-0148A as treatment for depression
March 10, 2021 | proactiveinvestors.com

BetterLife Enters Research Agreement with Carleton University for TD-0148A Depression Studies
March 8, 2021 | finance.yahoo.com

BetterLife Pharma hires Eurofins CDMO to manufacture LSD derivative TD-0148A
March 3, 2021 | proactiveinvestors.com

BetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing
March 3, 2021 | finance.yahoo.com

BetterLife Pharma files patent protection for its newest compound TD-010 to treat anxiolytic-use disorder
February 2, 2021 | proactiveinvestors.com

BetterLife Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use Disorder
February 2, 2021 | finance.yahoo.com

BetterLife Pharma inhaled coronavirus treatment passes six months of cold temperature tests
January 28, 2021 | proactiveinvestors.com

BetterLife Pharma partners with Eurofins Discovery for pharmacology studies of Eurofins' LSD-derived molecule TD-0148A
January 28, 2021 | proactiveinvestors.com

BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases
January 26, 2021 | benzinga.com

BetterLife Pharma inhaled coronavirus treatment passes six months of cold temperture tests
January 26, 2021 | proactiveinvestors.com

BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia
January 21, 2021 | benzinga.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

1984th out of 2,021 stocks

Pharmaceutical Preparations Industry

767th out of 772 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for BetterLife Pharma.

0.0 Community Rank

Outperform Votes
BetterLife Pharma has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
BetterLife Pharma has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about BetterLife Pharma and other stocks. Vote “Outperform” if you believe BETRF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BETRF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
BetterLife Pharma does not currently pay a dividend.
Dividend Growth
BetterLife Pharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BetterLife Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 34.77% of the stock of BetterLife Pharma is held by insiders.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of BetterLife Pharma is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BetterLife Pharma is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BetterLife Pharma has a P/B Ratio of 5.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$0.66

-0.01 (-1.49 %)

(As of 04/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive BETRF News and Ratings via Email

Sign-up to receive the latest news and ratings for BETRF and its competitors with MarketBeat's FREE daily newsletter.

BetterLife Pharma (OTCMKTS:BETRF) Frequently Asked Questions

What stocks does MarketBeat like better than BetterLife Pharma?

Wall Street analysts have given BetterLife Pharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BetterLife Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BetterLife Pharma?

BetterLife Pharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 15,500 shares, an increase of 3,000.0% from the March 15th total of 500 shares. Based on an average daily volume of 70,000 shares, the days-to-cover ratio is currently 0.2 days.
View BetterLife Pharma's Short Interest.

When is BetterLife Pharma's next earnings date?

BetterLife Pharma is scheduled to release its next quarterly earnings announcement on Monday, June 7th 2021.
View our earnings forecast for BetterLife Pharma.

Who are BetterLife Pharma's key executives?

BetterLife Pharma's management team includes the following people:

Dr. Ahmad Doroudian, Founder, CEO & Director (Age 61, Pay $133.33k)
Ms. Moira Ong C.A., CPA, CA, CFA, Chief Financial Officer (Age 46, Pay $120k)
Mr. Patrick Kroupa, Chief Psychedelics Officer
Mr. Justin Kirkland, Chief Psychedelics Scientist

Who are some of BetterLife Pharma's key competitors?

Some companies that are related to BetterLife Pharma include Guardion Health Sciences (GHSI), Cumberland Pharmaceuticals (CPIX), Addex Therapeutics (ADDXF), Kintara Therapeutics (KTRA), Panbela Therapeutics (PBLA), Bellerophon Therapeutics (BLPH), Qualigen Therapeutics (QLGN), Auris Medical (EARS), Reviva Pharmaceuticals (RVPH), Acer Therapeutics (ACER), Bio-Path (BPTH), Adial Pharmaceuticals (ADIL), MusclePharm (MSLP), Histogen (HSTO) and Sonnet BioTherapeutics (SONN).
View all of BETRF's competitors.

What is BetterLife Pharma's stock symbol?

BetterLife Pharma trades on the OTCMKTS under the ticker symbol "BETRF."

How do I buy shares of BetterLife Pharma?

Shares of BETRF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BetterLife Pharma's stock price today?

One share of BETRF stock can currently be purchased for approximately $0.66.

How much money does BetterLife Pharma make?

BetterLife Pharma has a market capitalization of $11.37 million.

How many employees does BetterLife Pharma have?

BetterLife Pharma employs 7 workers across the globe.

What is BetterLife Pharma's official website?

The official website for BetterLife Pharma is www.abetterlifepharma.com.

Where are BetterLife Pharma's headquarters?

BetterLife Pharma is headquartered at 1275 WEST 6TH AVENUE, VANCOUVER A1, V6H 1A6.

How can I contact BetterLife Pharma?

BetterLife Pharma's mailing address is 1275 WEST 6TH AVENUE, VANCOUVER A1, V6H 1A6. The company can be reached via phone at (604) 805-7783 or via email at [email protected]

This page was last updated on 4/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here